Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 536-545

  Jørgensen, Kristin Kaasen ^a   Grzyb, Krzysztof ^b   Lundin, Knut E A ^c   Clausen, Ole Petter F ^a,b   Aamodt, Geir ^e   Schrumpf, Erik ^a   Vatn, Morten H ^a,d   Boberg, Kirsten Muri ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Crohn's disease; inflammatory bowel disease; liver transplantation; primary sclerosing cholangitis; ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COLON RESECTION; COLONOSCOPY; DISEASE DURATION; ENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; ILEOCOLONOSCOPY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADENOMA; ADOLESCENT; ADULT; AGED; CARCINOMA; CECAL NEOPLASMS; CHILD; CHOLANGITIS, SCLEROSING; COLON; COLONIC NEOPLASMS; COLONOSCOPY; FEMALE; HUMANS; ILEITIS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; LINEAR MODELS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84857296115     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21699     Document Type: Article

References (40)

1. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol. 2003; 38: 1176-1183. (Pubitemid 37518603)
2. Schrumpf E, Boberg KM,. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001; 15: 553-562. (Pubitemid 32750293)
3. Fausa O, Schrumpf E, Elgjo K,. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991; 11: 31-39.
4. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 91-96. (Pubitemid 40007225)
5. Broome U, Bergquist A,. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006; 26: 31-41. (Pubitemid 43320725)
6. Joo M, Abreu-E-Lima, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009; 33: 854-862.
7. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995; 22: 1404-1408.
8. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009; 50: 158-164.
9. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56: 48-54. (Pubitemid 41115048)
10. Oshitani N, Jinno Y, Sawa Y, et al. Does colitis associated with primary sclerosing cholangitis represent an actual subset of ulcerative colitis? Hepatogastroenterology. 2003; 50: 1830-1835. (Pubitemid 37467944)
11. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980; 21: 870-877. (Pubitemid 11198911)
12. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134: 975-980. (Pubitemid 351451987)
13. Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998; 43: 29-32. (Pubitemid 28335486)
14. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006; 12: 543-550. (Pubitemid 43977734)
15. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629. (Pubitemid 18010466)
16. Noffsinger A, Fenoglio-Preiser C, Maru D, et al. Inflammatory bowel disease. In:, West King D, ed. Atlas of Nontumor Pathology. Gastrointestinal Diseases. Washington DC: ARP Press; 2007: 675-700.
17. Odze R, Antonioli D, Peppercorn M, et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative-colitis. Am J Surg Pathol. 1993; 17: 869-875. (Pubitemid 23245919)
18. Yantiss RK, Odze RD,. Pitfalls in the interpretation of nonneoplastic mucosal biopsies in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 890-904. (Pubitemid 46496630)
19. Aadland E, Schrumpf E, Fausa O, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol. 1987; 22: 655-664. (Pubitemid 17134654)
20. Schrumpf E, Elgjo K, Fausa O, et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol. 1980; 15: 689-697. (Pubitemid 11225943)
21. Lundqvist K, Broome U,. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997; 40: 451-456. (Pubitemid 27172624)
22. Moayyeri A, Daryani NE, Bahrami H, et al. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol. 2005; 20: 366-370. (Pubitemid 40469335)
23. Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008; 14: 3497-3503.
24. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44: 431-440.
25. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996; 31: 260-266.
26. Moum B, Ekbom A, Vatn MH, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999; 94: 1564-1569. (Pubitemid 29260447)
27. Niv Y, Bat L, Ron E, et al. Change in the extent of colonic involvement in ulcerative colitis: a colonoscopic study. Am J Gastroenterol. 1987; 82: 1046-1051. (Pubitemid 18047452)
28. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753. (Pubitemid 43764536)
29. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999; 94: 1643-1649. (Pubitemid 29260459)
30. Lindberg BU, Broome U, Persson B,. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001; 44: 77-85. (Pubitemid 32105878)
31. Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2009; 15: 1331-1336.
32. Moncrief KJ, Savu A, Ma MM, et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation-a single-centre experience. Can J Gastroenterol. 2010; 24: 40-46.
33. MacLean AR, Lilly L, Cohen Z, et al. Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. Dis Colon Rectum. 2003; 46: 1124-1128. (Pubitemid 36992998)
34. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002; 35: 380-384. (Pubitemid 34106378)
35. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006; 6: 1422-1429. (Pubitemid 44030325)
36. Karlsen TH, Boberg KM, Vatn M, et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun. 2007; 8: 275-278. (Pubitemid 46672059)
37. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010; 138: 1102-1111.
38. Karlsen TH, Hampe J, Wiencke K, et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol. 2007; 102: 115-121. (Pubitemid 46072051)
39. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998; 33: 99-103. (Pubitemid 28114077)
40. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51: 660-678.